Pricing

Paradigm Biopharma

0 followers

‌

Paradigm Biopharma (PAR) listed on the ASX in August 2015. Paradigm Biopharma's focus is on repurposing pentosan polysulphate sodium (PPS) for the treatment of diseases sustained by inflammation, where a key feature of the activity of PPS is its anti-inflammatory and tissue regenerative properties.

Industries

Headquarters

Melbourne, Australia

Employees

Links

Org chart

Founder & Chairman

Paul Rennie

Collapse

Director of Investor Relations

Michelle Coffey

Global Head of Regulatory Affairs

Chief Medical Officer and Executive Director

Donna Skerrett M.D. Msc

Chief Medical Officer

Catherine Stapledon

R&d Translational Scientist

Clinical Operations Lead

Director Of Business Operations

Teams

Leadership Team

3 members

Clinical Operations Team

3 members

Regulatory and Scientific Affairs Team

3 members

Finance and Investor Relations Team

2 members

Similar companies

Australian National University Entrepreneurship Club

4 followers

Takeda Pharmaceutical

118 followers

Lundbeck

31 followers

Apellis Pharmaceuticals

7 followers

Swedish Orphan Biovitrum

5 followers

Curia Global

4 followers

Empower Pharmacy

3 followers

Getz Pharma

41 followers

Grifols

21 followers

Vial

5 followers

Macquarie Group

100 followers

Explore companies